The United Bio-Technology (Hengqin) Co., Ltd.
The United Bio-Technology (Hengqin) Co., Ltd.
Explore linked clinical trials.9 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Diet and Exercise Alone（UNIGUIDE-1） | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, type 2 diabetes mellitus | Recruiting | Phase 3 | 2026-09-15 | NCT07659574 | |
| A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Subcutaneous UBT38006 Injection in Healthy Adult Males | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, type 2 diabetes mellitus | Recruiting | Phase 1 | 2026-09-15 | NCT07630233 | |
| Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2) | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, type 2 diabetes mellitus | Recruiting | Phase 3 | 2026-09-14 | NCT07653477 | |
| UBT251 Injection Phase Ⅲ Study (OSA-PAP) | Apnea, Body Weight, Dyssomnias, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Respiration Disorders, Signs and Symptoms, Sleep Disorders, Intrinsic, nervous system disorder, nutritional disorder, obesity disorder, obstructive sleep apnea syndrome, overnutrition, respiratory system disorder, sleep apnea syndrome, sleep-wake disorder | Not yet recruiting | Phase 3 | 2026-09-08 | NCT07806851 | |
| Phase I Drug-Drug Interaction Study of UBT251 Injection in Participants With Overweight or Obesity | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Recruiting | Phase 1 | 2026-08-25 | NCT07785934 | |
| UBT251 Injection Phase Ⅲ Study (OSA-NPAP) | Apnea, Body Weight, Dyssomnias, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Respiration Disorders, Signs and Symptoms, Sleep Disorders, Intrinsic, nervous system disorder, nutritional disorder, obesity disorder, obstructive sleep apnea syndrome, overnutrition, respiratory system disorder, sleep apnea syndrome, sleep-wake disorder | Not yet recruiting | Phase 3 | 2026-08-25 | NCT07767942 | |
| UBT251 Injection Phase Ⅲ Study (Overweight or Obesity) | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Not yet recruiting | Phase 3 | 2026-06-15 | NCT07648225 | |
| UBT251 Injection Phase II Clinical Study (CKD) | Body Weight, Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Nutritional and Metabolic Diseases, Overweight, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Urogenital Diseases, chronic renal failure syndrome, kidney disorder, kidney failure, nutritional disorder, obesity disorder, overnutrition, urinary system disorder | Recruiting | Phase 2 | 2025-11-25 | NCT07134335 | |
| A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) | Metabolic Dysfunction-associated Steatohepatitis (MASH) | Recruiting | Phase 2 | 2025-11-20 | NCT07145151 |